-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Langerhans Cell Histiocytosis: Promises and Caveats of Targeted Therapies in High-risk and CNS Disease

Program: Education Program
Session: How Do We Enhance Results in Rare Hematologic Malignancies?
Hematology Disease Topics & Pathways:
Biological therapies, Combination therapy, Diseases, Therapies, Adverse Events, Myeloid Malignancies
Sunday, December 10, 2023, 9:30 AM-10:45 AM

Oussama Abla, MD

University of Toronto, Hospital for Sick Children- Division of Hematology/Oncology, Toronto, ON, Canada

Disclosures: Abla: Springworks Therapeutics: Consultancy, Honoraria.

See more of: How Do We Enhance Results in Rare Hematologic Malignancies?
See more of: Education Program
Previous Presentation | Next Presentation >>